DEA, HHS finalize rule allowing telehealth drug treatment
- The Biden administration finalized a rule allowing telehealth providers to prescribe six months of buprenorphine without an in-person visit, as stated by the Drug Enforcement Administration and the Substance Abuse and Mental Health Services Administration.
- The final rule aims to expand access to opioid use disorder treatments and will take effect 30 days after publication in the Federal Register, according to the announcement by the DEA.
- The DEA will create a special registration process for providers to prescribe controlled substances via telemedicine, fulfilling a mandate from Congress dating back to 2008, as noted in the new regulations.
- The rules also impose new requirements to prevent misuse of buprenorphine, including checking state prescription databases, which advocates argue may complicate access to treatment, as expressed by the Alliance for Connected Care.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left0Leaning Right0Center4Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage